Skip to main content
Eurobio Scientific logo

Eurobio Scientific — Investor Relations & Filings

Ticker · ALERS ISIN · FR0013240934 LEI · 969500IQEUEH806GE257 PA Manufacturing
Open in API
Filings indexed 198 across all filing types
Latest filing 2022-01-11 Regulatory Filings
Country FR France
Listing PA ALERS

About Eurobio Scientific

https://www.eurobio-scientific.com

Eurobio Scientific is an integrated company specializing in in vitro diagnostics (IVD). Its activities cover the entire value chain, from research and development to the manufacturing and commercialization of specialty diagnostic products. The company's core focus areas are transplantation, oncology, and infectious diseases. In transplantation, it provides reagents, software for transplant matching and chimerism monitoring, and culture media for cornea grafts. For oncology, it develops and manufactures prognostic genomic tests for breast and prostate cancer. The group also markets a comprehensive portfolio of molecular tests for detecting infectious diseases, alongside solutions for immunology, fertility, and dermatological conditions.

Recent filings

Filing Released Lang Actions
EUROBIO SCIENTIFIC LAUNCHES THE EXCLUSIVE DISTRIBUTION OF THE FIRST SALIVA SELF-TEST FOR HIV TESTING IN FRANCE
Regulatory Filings Classification · 99% confidence The document is a press release dated January 11, 2022, announcing an exclusive distribution contract for a new HIV self-test product (OraQuick®) in France. It details the product, market context, and company strategy. It also includes a section titled 'Next financial meeting' which schedules the release of '2021 FY revenues' on January 24, 2022. This structure—a news announcement about a business development, often including forward-looking dates for financial releases—is characteristic of an Earnings Release (ER) or a general Regulatory Filing (RNS). Since the core content is a significant business update (new exclusive contract) rather than just the financial results themselves, and it is not a transcript, presentation, or formal statutory report (like 10-K or IR), it fits best as a general announcement. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for a general press release announcing a material business event that doesn't fit the other specific categories, although it shares characteristics with an ER announcement. However, since it is a press release announcing a business development and not the actual financial results, RNS is the safest classification.
2022-01-11 English
EUROBIO SCIENTIFIC CONFIRME SON ELIGIBILITE AU DISPOSITIF PEA-PME
Regulatory Filings Classification · 95% confidence The document is a short press release dated January 10, 2022, confirming the eligibility of Eurobio Scientific shares for the PEA-PME investment scheme. It contains minimal financial detail, primarily focusing on a regulatory/tax status confirmation and announcing the date for the upcoming 2021 revenue release (January 24, 2022). Since it is not a full report (like 10-K or IR), nor a specific announcement like a dividend (DIV) or management change (MANG), and it is not a transcript (CT) or a presentation (IP), it fits best as a general regulatory announcement or miscellaneous filing. Given the options, 'Regulatory Filings' (RNS) is the most appropriate fallback for this type of brief, non-standard corporate update that doesn't fit the other specific categories.
2022-01-10 French
EUROBIO SCIENTIFIC : BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE
Transaction in Own Shares Classification · 95% confidence The document is titled "BILAN SEMESTRIEL DU CONTRAT DE LIQUIDITE" (Semi-annual statement of the liquidity contract) and reports on the status of a liquidity contract for EUROBIO SCIENTIFIC shares as of 31/12/2021, detailing shares and cash held, and transactions (buy/sell) during the second half of 2021. This type of regular, periodic disclosure related to market making or liquidity provision is a specific type of regulatory or market-related announcement. It is not a full Annual Report (10-K), an Earnings Release (ER), or a standard Interim Report (IR). It details specific financial/market operations related to share trading/management. Given the options, this document is a specific report detailing the status of a financial arrangement (liquidity contract) which is often required periodically. It is most closely related to ongoing financial/market disclosures. Since there isn't a specific 'Liquidity Contract Report' code, we must evaluate the closest fit. It is a periodic report detailing financial activity, but it is not a standard quarterly/interim report (IR) which focuses on P&L/Balance Sheet. It is a specific disclosure about share transactions and holdings managed under a contract. This fits best under a general regulatory/market disclosure category. However, since it is a detailed report on share transactions and cash balances related to market making, it is a specific type of financial disclosure. Given the options, and noting that it is a detailed report (not just an announcement of a report), it is not RPA or RNS unless it fails all others. It is not Director's Dealing (DIRS) as it concerns the company's liquidity contract, not insider trades. It is not a Capital Change (CAP/SHA/POS) as it reports on the *management* of existing shares under contract, not a structural change. The closest fit among the provided codes for a specific, periodic financial/market operation report that isn't a standard earnings report is often a specialized regulatory filing or a report detailing specific financial instruments/activities. Since it details transactions and balances, it is a specific financial report. Given the context of French market disclosures, these liquidity contract reports are often filed as regulatory updates. If we must choose from the list, and recognizing it is a detailed report, it is not a general 'Interim Report' (IR). It is a report on share transactions/holdings, which sometimes falls under 'Transaction in Own Shares' (POS) if the company is actively managing its float, but here it's managed by a third party under contract. Considering the detailed nature and the focus on share activity, 'POS' (Transaction in Own Shares) is plausible if the liquidity contract is viewed as a form of share management/repurchase program, but the document explicitly calls it a 'Liquidity Contract Statement'. Given the lack of a perfect fit, and its nature as a periodic disclosure of market activity, 'RNS' (Regulatory Filings/Miscellaneous) is a strong fallback, but let's re-examine 'POS'. A liquidity contract often involves the agent buying/selling shares on the market, which is functionally similar to a share repurchase program. However, the document is a *statement* about the contract status, not the announcement of a buyback program itself. Therefore, the most appropriate category for a specific, periodic, non-standard financial disclosure is the general regulatory filing category.
2022-01-04 French
Eurobio Scientific obtient le marquage CE de son test propriétaire pour le dépistage du Covid-19 et la détection des variants Omicron et Delta
Regulatory Filings Classification · 100% confidence The document is a press release dated December 13, 2021, announcing that Eurobio Scientific has obtained the CE marking for its proprietary COVID-19 screening and variant detection test (EBX 047). It details the technical capabilities of the test and its immediate availability. It also includes a forward-looking statement ('Avertissement') and contact information. This type of announcement, focusing on a specific operational or product development milestone, is typically classified as a general regulatory announcement or a specific operational update. Since it is not a full financial report (10-K, IR), an earnings release (ER), or a management discussion (MDA), and it is a formal announcement of a regulatory achievement (CE marking), it fits best under the general 'Regulatory Filings' (RNS) category, as it is a mandatory disclosure of a significant event, or potentially a 'Capital/Financing Update' (CAP) if the CE mark directly leads to immediate revenue, but RNS is a safer general fit for non-financial regulatory news. Given the context of a press release announcing a regulatory approval (CE marking), RNS (Regulatory Filings) is the most appropriate general classification for non-standard disclosures.
2021-12-13 French
EUROBIO SCIENTIFIC obtains CE marking for its proprietary test for Covid-19 screening and detection of the Omicron and Delta variants
Regulatory Filings Classification · 95% confidence The document is a press release dated December 13, 2021, announcing that Eurobio Scientific has obtained CE marking for a new COVID-19 test. It details the product's features, regulatory compliance (ISO 13485), and immediate availability. This type of announcement, focusing on a specific operational or regulatory achievement (like obtaining a certification or marking) that is not a standard financial report (10-K, IR, ER), typically falls under general regulatory announcements or news releases. Since it is not a formal financial filing, a management change, a dividend notice, or a specific legal update, the most appropriate category is the general 'Regulatory Filings' (RNS) as a catch-all for significant, non-standard corporate news releases, or potentially 'Capital/Financing Update' (CAP) if the CE mark is viewed as a major commercial milestone, but RNS is safer for general announcements. Given the content is a product/regulatory milestone announcement, RNS is the best fit among the provided options, as it is not an Earnings Release (ER) or an Interim Report (IR). The document length is moderate (4749 chars), but it is a complete announcement, not just a notice to download a report.
2021-12-13 English
EUROBIO SCIENTIFIC LANCE LE PREMIER TEST PCR PERMETTANT EN UNE SEULE REACTION LE DEPISTAGE DU VIRUS DU SARS-COV-2 ET LA DETECTION DES VARIANTS DELTA ET OMICRON
Regulatory Filings Classification · 93% confidence The document is a press release dated November 30, 2021, announcing the launch of a new proprietary PCR test (EurobioPlex SARS-CoV-2 Fast Screening & Variants Detection) for detecting SARS-CoV-2 and screening for Delta and Omicron variants. It details the product features, availability (RUO status pending CE marking), and includes forward-looking statements and contact information. This type of announcement, focusing on a new product launch or significant operational update, is typically classified as an Earnings Release (ER) if it contains key financial highlights, or more generally as a Regulatory Filing (RNS) if it's a general corporate announcement not fitting other specific categories like M&A or Capital Change. Since it announces a product launch and includes a future financial event date ('Chiffre d'affaires 2021 : 24 janvier 2022'), it functions as a corporate update. Given the options, it is not a full Annual Report (10-K), Interim Report (IR), or a specific financial event like a dividend (DIV) or capital change (CAP/SHA). It is a general corporate news release. The closest fit among the specific categories for a product launch announcement that isn't explicitly an Earnings Release (ER) or a specific regulatory filing is often RNS, but since it announces a key operational development and includes a future earnings date, it shares characteristics with an ER, although it lacks detailed financial figures. However, based on the structure (product announcement, forward-looking statements, contact info), it is a standard press release. In the absence of a dedicated 'Press Release' category, and given that it is not a transcript (CT), management discussion (MDA), or investor presentation (IP), the most appropriate general category for a significant, non-financial-statement corporate announcement is Regulatory Filings (RNS). If the document contained the actual quarterly results, it would be ER or IR. Since it's a product launch announcement, RNS is the best fit as a general regulatory/corporate disclosure.
2021-11-30 French

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.